Recent Patents

Assignee: Rappaport Family Institute for Research in the Medical Sciences

A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.

A method of altering peripheral B cell populations in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of depleting peripheral B cells in the subject, and wherein the subject does not have a hematologic cancer or an autoimmune disease, thereby altering the peripheral B cell populations in the subject.

A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype

Assignee: Technion Research & Development Foundation Ltd.

An isolated composition of matter is disclosed. The composition comprises a heterogeneous population of cells seeded on a scaffold, wherein the heterogeneous population of cells comprises cardiomyocytes, endothelial cells and fibroblast cells. Pharmaceutical compositions comprising same and uses thereof are also disclosed.

Assignee: Rappaport Family Institute for Research in the Medical Sciences

This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a diabetic subject, treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype; and methods of treating cardiovascular disease in subjects exhibiting the Haptoglobin Hp-2-2 genotype.

This invention relates to methods of reducing risk of developing cardiovascular complications in diabetic patients. Specifically, the invention relates to the use of haptoglobin genotyping for determining the importance of maintaining tight glycemic control in diabetic subjects expressing Hp 2-2 allele.

Assignee: Technion Research And Development Foundation Ltd.

Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder.

A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.

Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD
Methods of generating embryoid bodies (EBs) by culturing embryonic stem cells (ESCs) under static conditions followed by culturing the cells under dynamic conditions using e.g., a Glass Bulb-shaped Impeller (GBI) or shaking a culture vessel are provided. Also provided are methods of generating expanded and/or differentiated cells from the EBs of the invention and methods of using same for treating disorders requiring cell replacement therapy.

Assignee Technion Research & Development Foundation Ltd
Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from adult stem cells are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.